Sigrid Therapeutics STAR Trial of SiPore15TM Showing Rapid Progress
Stockholm, Sweden, 4th June 2019 - First-in-Class MSP (mesoporous silica particle) based therapy targets blood sugar and other metabolic risk factors Sigrid Therapeutics AB, a biotechnology company developing a new class of therapies for metabolic diseases and disorders, today announces that it has already completed treatment of 25% of patients in the STAR trial of its first-in-class medical device, SiPore15, and is well on track to finalize results by Q4 of this year. The Company also reports that treatment compliance is good and the safety profile continues to look positive. STAR aims